In a decisive legal development, Pfizer Inc. has secured final approval for a $50 million settlement to address a protracted multidistrict litigation that accused the company of conspiring to raise the cost of EpiPen injections. The US District Court for the District of Kansas, under the jurisdiction of Judge Daniel D. Crabtree, underscored the settlement’s importance, emphasizing its capacity to deliver immediate financial recovery for direct EpiPen purchasers.
Judge Crabtree, in his Tuesday order, acknowledged the settlement’s value, quoting that “this immediate recovery is more valuable than a ‘mere possibility’ that Class Members might achieve a more favorable outcome ‘after protracted and expensive litigation’ that may well last ‘many years in the future.’” This statement underscores the judicial preference for a prompt resolution rather than an uncertain, prolonged legal fight.
The case has captured significant attention due to its implications for pharmaceutical pricing practices. Alongside the $50 million earmarked for the settlement, class counsel has been awarded $16.7 million in attorneys’ fees. This financial arrangement reflects both the complexity and the high stakes involved in the litigation process.
The final approval marks the culmination of a legal battle that has seen numerous twists and turns, ultimately leading to a resolution that promises immediate benefits to those affected. The accord ensures that direct EpiPen purchasers will receive financial remuneration without the necessity of further litigation.
For more information, you can read the [original article](https://news.bloomberglaw.com/antitrust/pfizer-gets-final-approval-of-50-million-epipen-litigation-deal) on Bloomberg Law.